Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Mclaughlin

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Psychology Research and Behavior Management|December 24, 2021
A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management"Kenneth Blum, Bruce Steinberg, Marjorie C Gondre-Lewis, et al.
Annals of Neurology|September 27, 2014
Short-term risk of stroke after dizziness presentation. ReplyKevin A Kerber, Darin B Zahuranec, Devin L Brown, et al.
Journal of Systems and Integrative Neuroscience|September 11, 2018
"Dopamine homeostasis" requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America's drug epidemicKenneth Blum, Edward J Modestino, Marjorie Gondré-Lewis, et al.
Acta Scientific Neurology|March 8, 2021
Should We Embrace the Incorporation of Genetically Guided "Dopamine Homeostasis" in the Treatment of Reward Deficiency Syndrome (RSD) as a Frontline Therapeutic Modality?Kenneth Blum, Ali Raza, Tiffany Schultz, et al.
Current Psychopharmacology|September 1, 2021
Endorphinergic Enhancement Attenuation of Post-traumatic Stress Disorder (PTSD) <i>via</i> Activation of Neuro-immunological Function in the Face of a Viral PandemicKenneth Blum, Edward J Modestino, David Baron, et al.
Journal of Behavioral Addictions|July 14, 2015
Hypothesizing repetitive paraphilia behavior of a medication refractive Tourette's syndrome patient having rapid clinical attenuation with KB220Z-nutrigenomic amino-acid therapy (NAAT)Thomas Mclaughlin, Marlene Oscar-Berman, Thomas Simpatico, et al.
Journal of Personalized Medicine|December 29, 2022
Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia's Effect on Addictive and Non-Addictive Behaviors in a Nuclear FamilyCatherine A Dennen, Kenneth Blum, Abdalla Bowirrat, et al.
Journal of Reward Deficiency Syndrome and Addiction Science|July 3, 2018
Hypothesizing Las Vegas and Sutherland Springs Mass Shooters Suffer from Reward Deficiency Syndrome: "Born Bad"Thomas McLaughlin, Kenneth Blum, Bruce Steinberg, et al.
Journal of Personalized Medicine|April 3, 2021
A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis RestorationKenneth Blum, Shan Kazmi, Edward J Modestino, et al.
Current Psychopharmacology|May 21, 2020
In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk TestingKenneth Blum, David Baron, Lisa Lott, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Psychology Research and Behavior Management|December 24, 2021
A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management"Kenneth Blum, Bruce Steinberg, Marjorie C Gondre-Lewis, et al.
Annals of Neurology|September 27, 2014
Short-term risk of stroke after dizziness presentation. ReplyKevin A Kerber, Darin B Zahuranec, Devin L Brown, et al.
Journal of Systems and Integrative Neuroscience|September 11, 2018
"Dopamine homeostasis" requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America's drug epidemicKenneth Blum, Edward J Modestino, Marjorie Gondré-Lewis, et al.
Acta Scientific Neurology|March 8, 2021
Should We Embrace the Incorporation of Genetically Guided "Dopamine Homeostasis" in the Treatment of Reward Deficiency Syndrome (RSD) as a Frontline Therapeutic Modality?Kenneth Blum, Ali Raza, Tiffany Schultz, et al.
Current Psychopharmacology|September 1, 2021
Endorphinergic Enhancement Attenuation of Post-traumatic Stress Disorder (PTSD) <i>via</i> Activation of Neuro-immunological Function in the Face of a Viral PandemicKenneth Blum, Edward J Modestino, David Baron, et al.
Journal of Behavioral Addictions|July 14, 2015
Hypothesizing repetitive paraphilia behavior of a medication refractive Tourette's syndrome patient having rapid clinical attenuation with KB220Z-nutrigenomic amino-acid therapy (NAAT)Thomas Mclaughlin, Marlene Oscar-Berman, Thomas Simpatico, et al.
Journal of Personalized Medicine|December 29, 2022
Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia's Effect on Addictive and Non-Addictive Behaviors in a Nuclear FamilyCatherine A Dennen, Kenneth Blum, Abdalla Bowirrat, et al.
Journal of Reward Deficiency Syndrome and Addiction Science|July 3, 2018
Hypothesizing Las Vegas and Sutherland Springs Mass Shooters Suffer from Reward Deficiency Syndrome: "Born Bad"Thomas McLaughlin, Kenneth Blum, Bruce Steinberg, et al.
Journal of Personalized Medicine|April 3, 2021
A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis RestorationKenneth Blum, Shan Kazmi, Edward J Modestino, et al.
Current Psychopharmacology|May 21, 2020
In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk TestingKenneth Blum, David Baron, Lisa Lott, et al.
Pageof 7